Overview

Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001

Status:
Not yet recruiting

Trial end date:
2023-01-31

Target enrollment:

Participant gender:

Summary

A randomised, double-blind, parallel-group, study comparing the analgesic effect of intranasal CT001 to intranasal sufentanil, intranasal ketamine or placebo for treatment of acute pain in adults undergoing surgical removal of an impacted mandibular third molar, where bone removal is judged to be needed.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Cessatech A/S

Treatments:

Ketamine
Sufentanil